

## FORM 7

### MONTHLY PROGRESS REPORT

Name of Listed Issuer: Bee Vectoring Technologies International Inc. (the "Issuer").

Trading Symbol: BEE

Number of Outstanding Listed Securities: 168,749,417 common shares ("Shares") were issued and outstanding as of February 29, 2024

Date: March 6, 2024 (for the month of February 2024)

This Monthly Progress Report must be posted before the opening of trading on the fifth trading day of each month. This report is not intended to replace the Issuer's obligation to separately report material information forthwith upon the information becoming known to management or to post the forms required by Exchange Policies. If material information became known and was reported during the preceding month to which this report relates, this report should refer to the material information, the news release date and the posting date on the Exchange website.

This report is intended to keep investors and the market informed of the Issuer's ongoing business and management activities that occurred during the preceding month. Do not discuss goals or future plans unless they have crystallized to the point that they are "material information" as defined in the Policies. The discussion in this report must be factual, balanced and non-promotional.

#### General Instructions

- (a) Prepare this Monthly Progress Report using the format set out below. The sequence of questions must not be altered nor should questions be omitted or left unanswered. The answers to the items must be in narrative form. State when the answer to any item is negative or not applicable to the Issuer. The title to each item must precede the answer.
- (b) The term "Issuer" includes the Issuer and any of its subsidiaries.
- (c) Terms used and not defined in this form are defined or interpreted in Policy 1 – Interpretation and General Provisions.

## Report on Business

1. Provide a general overview and discussion of the development of the Issuer's business and operations over the previous month. Where the Issuer was inactive disclose this fact.

The Issuer, an agriculture technology company, is a market disruptor with a significant global market opportunity in the \$240 billion crop protection and fertilizer market. The Issuer has pioneered a natural precision agriculture system that replaces chemical pesticides and wasteful plant protection product spray applications by delivering biological pesticide alternatives to crops using commercially grown bees. The Issuer's award-winning technology, precision vectoring, is completely harmless to bees and allows minute amounts of naturally-derived pesticides (called biologicals) to be delivered directly to blooms, providing improved crop protection and yield results than traditional chemical pesticides - and improving the health of the soil, the microbiome and the environment. Currently, the Issuer has over 65 granted patents, over 35 patents pending in all major agricultural countries worldwide, and has US EPA registration of its VECTORITE™ with CR-7 (EPA Registration No. 90641-2) for sale as a registered biological fungicide for use on the labelled crops.

2. Provide a general overview and discussion of the activities of management.

During the month of February 2024, management's principal activities consisted of:

- attending to general administrative matters;
- the preparation and filing of the Issuer's interim financial statements and accompanying management discussion and analysis for the 1<sup>st</sup> quarter ended December 31, 2023;
- providing an update with regards to the Issuer's strategic partnership strategy with several multinational agriculture companies by allocating resources to tap into large, established channels to access more buyers, enter more distribution and marketing channels, and utilize sales teams that are experienced and deeply embedded in key regions and key crops around the world. The Issuer is also pursuing partnerships in the large soybean seed treatment market, where one of the multinationals has conducted multi-year trials with BVT's CR-7. Multi-year trials have shown CR-7 to be an effective treatment against Sudden Death Syndrome (SDS), a huge challenge for soybean growers;
- announcing that Agrobío SL (Spain) commenced trials of the Issuer's natural precision agriculture system in December. The trial is a part of Agrobío's participation in the EU-funded ADOPT-IPM project, which is part of the European Commission's Horizon Research and Innovations Actions (Horizon RIA), a major initiative intended to boost the EU's growth and competitiveness in areas such as tackling climate change.

3. Describe and provide details of any new products or services developed or offered. For resource companies, provide details of new drilling, exploration or production programs and acquisitions of any new properties and attach any mineral or oil and gas or other reports required under Ontario securities law.

There were no new products or services developed or offered during the month of February 2024.

4. Describe and provide details of any products or services that were discontinued. For resource companies, provide details of any drilling, exploration or production programs that have been amended or abandoned.

There were no products or services discontinued during the month of February 2024.

5. Describe any new business relationships entered into between the Issuer, the Issuer's affiliates or third parties including contracts to supply products or services, joint venture agreements and licensing agreements etc. State whether the relationship is with a Related Person of the Issuer and provide details of the relationship.

The Issuer announced that Agrobío SL (Spain) commenced trials of BVT's natural precision agriculture system. The Agrobío trial is being conducted in greenhouse tomato crops in Spain, measuring the BVT system compared to traditional standard spray programs for efficacy in combating Botrytis (gray mold). It is using BVT's VectorHive system for bumblebees and proprietary Vectorite with CR-7 biofungicide. The trial will last until the end of the tomato crop cycle, which is approximately eight to ten months.

Agrobío is a bio-factory that produces beneficial insects for pest control and bumblebees for natural pollination. Founded in 1995 in Almería, Spain, Agrobío has pioneered Spanish bumblebee production and grown into a multinational business supplying growers across Europe, Morocco and Turkey.

6. Describe the expiry or termination of any contracts or agreements between the Issuer, the Issuer's affiliates or third parties or cancellation of any financing arrangements that have been previously announced.

No contracts or agreements between the Issuer, the Issuer's affiliates or third parties expired or were cancelled and no previously announced financing arrangements were cancelled during the month of February 2024.

7. Describe any acquisitions by the Issuer or dispositions of the Issuer's assets that occurred during the preceding month. Provide details of the nature of the assets acquired or disposed of and provide details of the consideration paid or payable together with a schedule of payments if applicable, and of any valuation. State how the consideration was determined and whether the acquisition was from or the

disposition was to a Related Person of the Issuer and provide details of the relationship.

There were no acquisitions or dispositions of the Issuer's assets during the preceding month of January 2024.

8. Describe the acquisition of new customers or loss of customers.

There were no new customers or loss of customers during the month of February 2024.

9. Describe any new developments or effects on intangible products such as brand names, circulation lists, copyrights, franchises, licenses, patents, software, subscription lists and trade-marks.

There were no new developments or effects on intangible products that occurred during the month of February 2024.

10. Report on any employee hirings, terminations or lay-offs with details of anticipated length of lay-offs.

There were no employee hirings, terminations or lay-offs during the month of February 2024.

11. Report on any labour disputes and resolutions of those disputes if applicable.

There were no labour disputes during the month of February 2024.

12. Describe and provide details of legal proceedings to which the Issuer became a party, including the name of the court or agency, the date instituted, the principal parties to the proceedings, the nature of the claim, the amount claimed, if any, if the proceedings are being contested, and the present status of the proceedings.

There were no legal proceedings to which the Issuer became party to during the month of February 2024.

13. Provide details of any indebtedness incurred or repaid by the Issuer together with the terms of such indebtedness.

14. There was no indebtedness incurred or repaid by the Issuer together with the terms of such indebtedness during the month of February 2024.

15. Provide details of any securities issued and options or warrants granted.

There were no securities issued and options or warrants granted during the month of February 2024.

16. Provide details of any loans to or by Related Persons.

There were no loans made to or by Related Persons of the Issuer during the month of February 2024.

17. Provide details of any changes in directors, officers or committee members.

As at February 29, 2024, the directors and officers of the Issuer are as follows:

Ashish Malik	Director, Chief Executive Officer, President and member of the audit committee
Kyle Appleby	Chief Financial Officer and Corporate Secretary
Michael Collinson	Director, Chairman and member of the audit committee
James Molyneux	Director, Chair of audit committee

18. Discuss any trends which are likely to impact the Issuer including trends in the Issuer's market(s) or political/regulatory trends.

The trends and risks which are likely to impact the Issuer are detailed in the Issuer's MD&A for the year ended September 30, 2023 dated as of January 29, 2024 under the headings "FINANCIAL INSTRUMENTS", "OTHER RISKS AND UNCERTAINTIES" and "RISKS AND UNCERTAINTIES". The MD&A is available on the Issuer's SEDAR+ profile at [www.sedarplus.ca](http://www.sedarplus.ca).

## Certificate of Compliance

The undersigned hereby certifies that:

1. The undersigned is a director and/or senior officer of the Issuer and has been duly authorized by a resolution of the board of directors of the Issuer to sign this Certificate of Compliance.
2. As of the date hereof there were is no material information concerning the Issuer which has not been publicly disclosed.
3. The undersigned hereby certifies to the Exchange that the Issuer is in compliance with the requirements of applicable securities legislation (as such term is defined in National Instrument 14-101) and all Exchange Requirements (as defined in CNSX Policy 1).
4. All of the information in this Form 7 Monthly Progress Report is true.

Dated March 6, 2024

Ashish Malik  
Name of Director or Senior  
Officer

"Ashish Malik"  
Signature

President & CEO  
Official Capacity

<b>Issuer Details</b>	For Month End	Date of Report
Name of Issuer		YYYY/MM/D
Bee Vectoring Technologies International Inc.	February 2024	2024/3/06
Issuer Address		
4160 Sladeview Crescent, #7		
City/Province/Postal Code	Issuer Fax No.	Issuer Telephone No.
Mississauga, ON L5L 0A1	(604) 687-3141	(604) 687-2038
Contact Name	Contact Position	Contact Telephone No.
Ashish Malik	President & CEO	(604) 687-2038
Contact Email Address	Web Site Address	
<a href="mailto:amalik@beevt.com">amalik@beevt.com</a>	<a href="http://www.beevt.com/">http://www.beevt.com/</a>	